Inflammatory local recurrence after breast-conservation therapy for noninflammatory breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 431-432

  Huston, Tara L ^a   Simmons, Rache M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Breast cancer; Breast conservation therapy; Inflammatory breast carcinoma; Local recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSERVATIVE TREATMENT; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; MASTECTOMY; PROGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTITIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 23244456040     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000145288.23823.9d     Document Type: Article

References (4)

1. Osborne MP, Simmons RM. Salvage surgery for recurrence after breast conservation. World J Surg. 1994;18:93-97.
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014-1024.
3. Kaufman M. Review of known prognostic variables. Results Probl Cell Differ. 2000;140:77-87.
4. Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-FU, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851-855.